Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ECE1 | P42892 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019026 | 1.00 | FOLH1 (0.52) | FOLH1HTTALDH1A1NAALAD2TACR1 | |
| Hydrochloric Acid SCHEMBL1161942 | 0.98 | FOLH1 (0.51) | FOLH1HTTALDH1A1NAALAD2TACR1 | |
| SCHEMBL23901485 | 0.90 | ALDH1A1 (0.53) | ALDH1A1TACR1ACE | |
| SCHEMBL25645317 | 0.86 | CTSK (0.52) | ALDH1A1TACR1 | |
| SCHEMBL27012488 | 0.85 | FOLH1 (0.50) | FOLH1HTTALDH1A1NAALAD2TACR1 | |
| SCHEMBL30665417 | 0.85 | TACR1 (0.59) | FOLH1HTTALDH1A1NAALAD2TACR1 | |
| SCHEMBL17642318 | 0.85 | FOLH1 (0.52) | FOLH1HTTALDH1A1NAALAD2MME | |
| SCHEMBL5019111 | 0.84 | ALDH1A1 (0.51) | HTTALDH1A1TACR1 | |
| SCHEMBL29166036 | 0.84 | FOLH1 (0.54) | FOLH1HTTALDH1A1NAALAD2MME | |
| SCHEMBL29166038 | 0.84 | FOLH1 (0.54) | FOLH1HTTALDH1A1NAALAD2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20170097567-A1 | METHOD FOR PRODUCING POLYMER | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-04-06 | — | — | US | disclosed |
| CN-102471349-B | Conformationally constrained, fully synthetic macrocyclic compounds | 波利弗尔股份公司 | 2016-08-24 | — | — | CN | disclosed |
| US-20160229940-A1 | POLYMER, RESIST COMPOSITION, AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | disclosed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | disclosed |
| CN-102471349-A | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG | 2012-05-23 | — | — | CN | disclosed |
| EP-1040103-B1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-6413947-B1 | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| US-6268354-B1 | Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-31 | — | — | US | disclosed |
| CN-1282326-A | Anilide derivative, process for producing the same, and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-01-31 | — | — | CN | disclosed |
| CN-1282243-A | Pharmaceutical composition containing anilide derivative for antagonizing CCR5 | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-01-31 | — | — | CN | disclosed |
| US-6172061-B1 | AIDS THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| US-6166006-A | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1039899-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| EP-1040103-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999032100-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032468-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | FOLH1 1731/4885HTT 1605/4885ALDH1A1 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.